Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 20662624.
- Also identified by DOI 10.1086/655470 and PMC identifier 2919241.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In AIDS Clinical Trials Group protocols 384, A5095, and A5097s, we characterized relationships between 22 polymorphisms in CYP2B6, ABCB1, and CYP3A5; plasma efavirenz exposure; and/or treatment responses. A stepwise logistic regression procedure selected polymorphisms associated with reduced drug clearance adjusted for body mass index and the composite CYP2B6 516/983 genotype. Relationships between selected polymorphisms and treatment responses were characterized by competing risk methodology. Association analyses involved 821 individuals (317 for pharmacokinetics and 643 for treatment response). Models that included CYP2B6 516/983 genotype best predicted pharmacokinetics. Slow-metabolizer genotypes were associated with increased central nervous system events among white participants and decreased virologic failure among black participants.
Medical subject headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1
- Anti-HIV Agents
- Aryl Hydrocarbon Hydroxylases
- Benzoxazines
- Cytochrome P-450 CYP3A
- Oxidoreductases, N-Demethylating
- Polymorphism, Single Nucleotide
- Reverse Transcriptase Inhibitors